Download PDF
Horm Metab Res 2003; 35(3): 183-188
DOI: 10.1055/s-2003-39079
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Myocardial Perfusion Abnormalities in Patients with Active Acromegaly

B.  L.  Herrmann 1 , K.  Brandt-Mainz 2 , B.  Saller 1 , C.  Bruch 3 , H.  Wieneke 3 , C.  Kügler 4 , S.  Ferdin 1 , S.  Hahn 1 , R.  Erbel 3 , A.  Bockisch 2 , K.  Mann 1
  • 1 Division of Endocrinology, University of Essen, Germany
  • 2 Division of Nuclear Medicine, University of Essen, Germany
  • 3 Division of Cardiology, University of Essen, Germany
  • 4 Department of Angiology, University of Essen, Germany
Further Information

Publication History

Received 23 May 2002

Accepted after revision 14 October 2002

Publication Date:
07 May 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Cardiomyopathy is often seen in patients with a long history of acromegaly. In order to screen for perfusion abnormalities, patients with active acromegaly without evidence for coronary heart disease were examined by single photon emission computed tomography (SPECT). The study included a group of 11 strictly selected patients with active acromegaly (7 males and 4 females; age 51 ± 12 y [mean ± S.D.]) with elevated age-adjusted IGF-I levels (IGF-I 569 ± 193 µg/l; GH 31.2 ± 56.3 µg/l) compared to an age- and sex-matched non-acromegalic control group with comparable muscle mass index of the left ventricle (126 ± 41 active vs. 122 ± 33 g/m2 control group) and body mass index (26.6 ± 2.7 vs. 27.0 ± 5.0 kg/m2). To address this issue, myocardial perfusion was investigated by single photon emission computed tomography (SPECT) using a triple head gamma-camera. 70 MBq 201TlCl was injected, and post-stress (from bicycle ergometer) images were obtained. Images were interpreted quantitatively by bull's eye polary map (16 regions of the left ventricle) and were compared to the control group. In the patients with active acromegaly, the mean nuclide uptake of the 16 regions of the left ventricle after bicycle stress examination was lower than in the control group (82.99 ± 2.85 active vs 85.48 ± 1.29 control group, p < 0.01). Non-homogeneity of nuclide uptake was defined as the standard deviations of the 16 regions and was higher in patients with active acromegaly (11.11 ± 2.35 active vs. 8.77 ± 1.39 control group, p < 0.01). In conclusion, myocardial perfusion is impaired in patients with active acromegaly, thus representing an early stage of cardiac involvement in acromegaly that may be directly mediated by growth hormone excess.

Key words

Acromegaly - Impaired Myocardial Perfusion - Scintigraphy

References

  • 1 Drange M R, Fram N R, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource.  J Clin Endocrinol Metab. 2000;  85 168-174
    CrossrefPubMedGoogle Scholar
  • 2 Lombardi G, Colao A, Cuocolo A, Longobardi S, di Somma C, Orio F, Merola B, Nicolai E, Salvatore M. Cardiological aspects of growth hormone and insulin-like growth factor- I.  J Pediatr Endocrinol Metab. 1997;  10 553-560
    PubMedGoogle Scholar
  • 3 Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S, Merola B. Effect of growth hormone on cardiac function.  Horm Res. 1997;  48 38-42
    PubMedGoogle Scholar
  • 4 Kahaly G, Olshausen K V, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly.  Eur Heart J. 1992;  13 51-56
    PubMedGoogle Scholar
  • 5 Kahaly G, Stover C, Beyer J, Mohr-Kahaly S. Relation of endocrine and cardiac findings in acromegalics.  J Endocrinol Invest. 1992;  15 13-18
    PubMedGoogle Scholar
  • 6 Ozbey N, Oncul A, Bugra Z, Vural A, Erzengin F, Orhan Y, Buyukozturk K, Sencer E, Molvalilar S. Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage.  J Endocrinol Invest. 1997;  20 305-311
    PubMedGoogle Scholar
  • 7 Herrmann B L, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R, Mann K. Occurrence of ventricular late potentials in patients with active acromegaly.  Clin Endocrinol (Oxf). 2001;  55 201-207
    CrossrefPubMedGoogle Scholar
  • 8 Herrmann B L, Bruch C, Saller B, Bartel T, Ferdin S, Erbel R, Mann K. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy.  Clin Endocrinol (Oxf). 2002;  56 595-602
    CrossrefPubMedGoogle Scholar
  • 9 Galanti G, Cappelli B, Diricatti G, Mininni S, Vono M C, Gensini G F. Systolic and diastolic cardiac function in acromegaly. An echocardiographic study.  Ann Ital Med Int. 1996;  11 27-32
    PubMedGoogle Scholar
  • 10 Cuocolo A, Nicolai E, Fazio S, Pace L, Maurea S, Cittadini A, Sacca L, Salvatore M. Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography.  J Nucl Med. 1995;  36 196-201
    PubMedGoogle Scholar
  • 11 Sacca L, Cittadini A, Fazio S. Growth hormone and the heart.  Endocr Rev. 1994;  15 555-573
    CrossrefPubMedGoogle Scholar
  • 12 Lopez-Velasco R, Escobar-Morreale H F, Vega B, Villa E, Sancho J M, Moya-Mur J L, Garcia-Robles R. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?.  J Clin Endocrinol Metab. 1997;  82 1047-1053
    CrossrefPubMedGoogle Scholar
  • 13 Minniti G, Jaffrain-Rea M L, Moroni C, Baldelli R, Ferretti E, Cassone R, Gulino A, Tamburrano G. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics.  Clin Endocrinol (Oxf). 1998;  49 101-106
    CrossrefPubMedGoogle Scholar
  • 14 D'Angio C T, Ambati J, Phelps D L. Do urinary levels of vascular endothelial growth factor predict proliferative retinopathy?.  Curr Eye Res. 2001;  22 90-94
    CrossrefPubMedGoogle Scholar
  • 15 Kwak N, Okamoto N, Wood J M, Campochiaro P A. VEGF is major stimulator in model of choroidal neovascularization.  Invest Ophthalmol Vis Sci. 2000;  41 3158-3164
    PubMedGoogle Scholar
  • 16 Lip P L, Belgore F, Blann A D, Hope-Ross M W, Gibson J M, Lip G Y. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.  Invest Ophthalmol Vis Sci. 2000;  41 2115-2119
    PubMedGoogle Scholar
  • 17 Aiello L P, Avery R L, Arrigg P G, Keyt B A, Jampel H D, Shah S T, Pasquale L R, Thieme H, Iwamoto M A, Park J E. et al . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
    CrossrefPubMedGoogle Scholar
  • 18 Wells J A, Murthy R, Chibber R, Nunn A, Molinatti P A, Kohner E M, Gregor Z J. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.  Br J Ophthalmol. 1996;  80 363-366
    PubMedGoogle Scholar
  • 19 Nagai Y, Ando H, Nohara E, Yamashita H, Takamura T, Kobayashi K. Plasma levels of vascular endothelial growth factor in patients with acromegaly.  Horm Metab Res. 2000;  32 326-329
    PubMedGoogle Scholar
  • 20 Evans L M, Davies J S. Heterogeneous haemodynamics in acromegaly: evidence of endothelial dysfunction?.  Clin Endocrinol (Oxf). 1998;  49 711-712
    CrossrefPubMedGoogle Scholar
  • 21 Chanson P, Megnien J L, del Pino M, Coirault C, Merli I, Houdouin L, Harris A G, Levenson J, Lecarpentier Y, Simon A, Chemla D. Decreased regional blood flow in patients with acromegaly.  Clin Endocrinol (Oxf). 1998;  49 725-731
    CrossrefPubMedGoogle Scholar
  • 22 Wieneke H, Zander C, Eising E G, Haude M, Bockisch A, Erbel R. Non-invasive characterization of cardiac microvascular disease by nuclear medicine using single-photon emission tomography.  Herz. 1999;  24 515-521
    PubMedGoogle Scholar
  • 23 Astarita C, Nicolai E, Liguori E, Gambardella S, Rumolo S, Maresca F S. Dipyridamole-echocardiography and thallium exercise myocardial scintigraphy in the diagnosis of obstructive coronary or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina.  G Ital Cardiol. 1998;  28 996-1004
    PubMedGoogle Scholar
  • 24 Giustina A, Barkan A, Casanueva F F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85 526-529
    CrossrefPubMedGoogle Scholar
  • 25 Buell U, Stirner H, von Dahl J, Uebis R, Kleinhans E, Biedermann M, Grosse W, Simon H J. Quantitative evaluation of myocardial stress/rest 201TL SPECT: results of a ROI-based method in 108 patients with CHD.  Nuklearmedizin. 1987;  26 234-240
    PubMedGoogle Scholar
  • 26 Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods.  J Clin Endocrinol Metab. 2000;  85 4426-4433
    CrossrefPubMedGoogle Scholar
  • 27 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 28 Haffner S M, Miettinen H, Stern M P. The homeostasis model in the San Antonio Heart Study.  Diabetes Care. 1997;  20 1087-1092
    CrossrefPubMedGoogle Scholar
  • 29 Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.  J Clin Endocrinol Metab. 2000;  85 193-199
    CrossrefPubMedGoogle Scholar
  • 30 Moller N, Jorgensen J O, Abildgard N, Orskov L, Schmitz O, Christiansen J S. Effects of growth hormone on glucose metabolism.  Horm Res. 1991;  36 32-35
    PubMedGoogle Scholar
  • 31 Oscarsson J, Wiklund O, Jakobsson K E, Petruson B, Bengtsson B A. Serum lipoproteins in acromegaly before and 6 - 15 months after transsphenoidal adenomectomy.  Clin Endocrinol (Oxf). 1994;  41 603-608
    PubMedGoogle Scholar
  • 32 Tsuchiya H, Onishi T, Mogami H, Iida M. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy.  Endocrinol Jpn. 1990;  37 797-807
    PubMedGoogle Scholar
  • 33 Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.  J Clin Endocrinol Metab. 1999;  84 17-23
    CrossrefPubMedGoogle Scholar
  • 34 Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, di Somma C, di Sarno A, Giaccio A, Lombardi G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.  J Endocrinol Invest. 1999;  22 40-47
    PubMedGoogle Scholar
  • 35 Fazio S, Cittadini A, Cuocolo A, Merola B, Sabatini D, Colao A, Biondi B, Lombardi G, Sacca L. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.  J Clin Endocrinol Metab. 1994;  79 441-446
    CrossrefPubMedGoogle Scholar
  • 36 Fazio S, Cittadini A, Sabatini D, Merola B, Colao A M, Biondi B, Lombardi G, Sacca L. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study.  Eur Heart J. 1993;  14 26-33
    PubMedGoogle Scholar
  • 37 Takata J, Counihan P J, Gane J N, Doi Y, Chikamori T, Ozawa T, McKenna W J. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain.  Am J Cardiol. 1993;  72 211-217
    CrossrefPubMedGoogle Scholar
  • 38 Wackers F J. Myocardial perfusion imaging in ischemic heart disease anno 1990.  Curr Opin Cardiol. 1991;  6 590-601
    PubMedGoogle Scholar
  • 39 Wackers F J. The birth of a new radiopharmaceutical. Clinical investigative perspective.  J Nucl Cardiol. 1995;  2 75-77
    PubMedGoogle Scholar
  • 40 Hutchins P M, Lynch C D, Cooney P T, Curseen K A. The microcirculation in experimental hypertension and aging.  Cardiovasc Res. 1996;  32 772-780
    CrossrefPubMedGoogle Scholar
  • 41 Lie J T. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.  Am Heart J. 1980;  100 41-52
    CrossrefPubMedGoogle Scholar
  • 42 Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F, Leri A, Kajstura J, Anversa P, Maseri A. Cell death in acromegalic cardiomyopathy.  Circulation. 1999;  99 1426-1434
    CrossrefPubMedGoogle Scholar
  • 43 Feinstein S B, Voci P, Pizzuto F. Noninvasive surrogate markers of atherosclerosis.  Am J Cardiol. 2002;  89 31C-43C; discussion 43C-44C
    CrossrefPubMedGoogle Scholar
  • 44 Yamashita N, Nakayama Y, Tsumura K, Nishijima T, Ueda H, Yoshimaru K, Hayashi T, Yoshikawa J. Pulsatility of brachial artery pressure is associated with an increased risk of coronary artery disease in men.  J Hypertens. 2001;  19 1589-1593
    CrossrefPubMedGoogle Scholar
  • 45 Anderson T J, Uehata A, Gerhard M D, Meredith I T, Knab S, Delagrange D, Lieberman E H, Ganz P, Creager M A, Yeung A C. et al . Close relation of endothelial function in the human coronary and peripheral circulations.  J Am Coll Cardiol. 1995;  26 1235-1241
    CrossrefPubMedGoogle Scholar
  • 46 Enderle M D, Schroeder S, Ossen R, Meisner C, Baumbach A, Haering H U, Karsch K R, Pfohl M. Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease.  Heart. 1998;  80 349-354
    PubMedGoogle Scholar
  • 47 Heusch G. Hibernating myocardium.  Physiol Rev. 1998;  78 1055-1085
    PubMedGoogle Scholar
  • 48 Hasdai D, Nielsen M F, Rizza R A, Holmes D R, Richardson D M, Cohen P, Lerman A. Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia.  Hypertension. 1999;  34 89-95
    PubMedGoogle Scholar
  • 49 Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.  Am J Physiol. 1986;  250 E269-E273
    PubMedGoogle Scholar
  • 50 Rizza R A, Mandarino L J, Gerich J E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization.  Diabetes. 1982;  31 663-669
    CrossrefPubMedGoogle Scholar
  • 51 Lepej J, Spisiakova D, Hrnciar J, Okapcova J, Szentivanyi M, Kurray P. Thallium scintigraphy of the myocardium in evaluation of patients with insulin resistance syndrome and microvascular angina pectoris.  Vnitr Lek. 2000;  46 205-212
    PubMedGoogle Scholar
  • 52 Pinkney J H, Stehouwer C D, Coppack S W, Yudkin J S. Endothelial dysfunction: cause of the insulin resistance syndrome.  Diabetes. 1997;  46 S9-S13
    PubMedGoogle Scholar

B. L. Herrmann, M.D.

University of Essen · Center of Internal Medicine · Division of Endocrinology

Hufelandstr. 55 · 45122 Essen · Germany

Phone: + 49 (201) 723-2821

Fax: + 49 (201) 723-5972

Email: burkhard.herrmann@uni-essen.de